HALOZYME THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances)·SAN DIEGO, CA·FY end 12/31·CIK 1159036

Overview Financials Compensation Governance Insiders Filings

Named Executive Officers

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Helen I. TorleyPresident and Chief Executive Officer	$1.0M	$19.4M	$1.7M	$1.1M	$18.6K	$23.2M
Nicole LaBrosseSenior Vice President, Chief Financial Officer	$604.2K	$3.0M	$525.0K	$462.2K	$12.3K	$4.6M
Mark SnyderSenior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary	$619.0K	$3.0M	$525.0K	$394.6K	$17.8K	$4.5M
Cortney Caudill	$561.0K	$1.7M	$512.5K	$382.5K	$9.2K	$3.2M
Michael J. LaBarreFormer Senior Vice President, Chief Technical Officer	$120.3K	$1.6M	$276.4K	—	$90.2K	$2.1M

CEO pay mix

Helen I. Torley · FY 2025

Stock awards$19.4M84%

Performance bonus$1.1M5%

Salary$1.0M4%

Other$1.7M7%

Performance vs. pay

Item 402(v) Pay-Versus-Performance disclosure data not yet ingested for this company. Mandatory only for FYs ending on/after Dec 16, 2022 — older companies may not have filed it yet.

CEO comp · median worker · ratio — multi-year trend

Need at least two fiscal years of proxy data to draw the trend line. The ingestion worker will populate prior-year proxies as it processes them.